行情

CERC

CERC

Cerecor
NASDAQ

实时行情|Nasdaq Last Sale

2.380
+0.230
+10.70%
交易中 15:43 04/08 EDT
开盘
2.230
昨收
2.150
最高
2.510
最低
2.230
成交量
9.93万
成交额
--
52周最高
6.19
52周最低
1.520
市值
1.37亿
市盈率(TTM)
-6.2714
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CERC价格均价为11.00,最高价位12.00,最低价为10.00。

EPS

CERC 新闻

更多
  • 美联储会议纪要:经济前景面临“极大程度”不确定性
  • 新浪美股 · 1小时前
  • 经济复苏为时尚早 全球市场持续震荡 欧股收盘走低
  • 新浪财经综合 · 2小时前
  • 调查:四分之一的美国人因疫情封锁措施失业或减薪
  • 新浪美股 · 2小时前
  • 美国调查丨快递小哥不干了!
  • 央视 · 2小时前

所属板块

生物技术和医学研究
+3.02%
制药与医学研究
+2.86%

热门股票

代码
价格
涨跌幅

CERC 简况

Cerecor, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.
展开

微牛提供Cerecor Inc(NASDAQ-CERC)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CERC股票新闻,以帮助您做出投资决策。